• Sale of retail generics portfolio is part of the transformation strategy which refocused the Company on the US women’s healthcare and dermatology markets • Women’s Healthcare, Dermatology, and International generating contribution margin • Solid cash position combined with focused transformation strategy helps achieve profitability by the end of FY24 and deliver longer term growth • Announced an on-market share buyback for up to 10% of issued capital
Strategic Objectives for FY23 and FY24 • Successfully implement new commercial strategy for NEXTSTELLIS® in the US and Australia, to reach a breakeven annual run rate in the 1HFY24 for the US business • Capitalise on the strength of women’s health franchise by maximising opportunities with all products and delivering positive EBITDA • Successfully employ US differentiated channel strategy to improve margins in dermatology and women’s health, while providing better patient access • Broaden portfolio with complementary accretive products that leverage existing commercial infrastructure characterized by gradual growth or increase."despite the accretive sediment measured, there is a clear shoreline erosion"
MYX Price at posting:
$3.47 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)